AGE AND GENDER CHARACTERISTICS OF THE ANTIPSYCHOTIC DRUG PALIPERIDONE USE IN THE THERAPY OF PARANOID SCHIZOPHRENIA IN THE REPUBLIC OF KAZAKHSTAN
Keywords:
schizophrenia, psychopharmacotherapy, antipsychotics, paliperidone.Abstract
Introduction. Schizophrenia is one of the most common mental disorders, leading to adverse social and economic consequences. Given the variety of its interrelated clinical and humanitarian impacts, schizophrenia is one of the most costly diseases for society. Therefore, the development of effective therapy methods for schizophrenia is an urgent problem not only for psychiatry but also for the public health of the Republic of Kazakhstan.
Aim of the study. To study the gender and age characteristics of the efficacy and tolerability of paliperidone in patients of Kazakh nationality with schizophrenia.
Material and methods. The study included 221 patients of Kazakh nationality with a clinically verified diagnosis of "Paranoid Schizophrenia" corresponding to the criteria of ICD-10 category F20.0. The study used clinical-psychopathological and psychometric methods (PANSS scale), followed by a comparative analysis of the efficacy and tolerability of paliperidone across specific age and gender groups.
Results. Gender and age characteristics of dynamics in the clinical presentation of paranoid schizophrenia during the use of paliperidone in persons of Kazakh nationality were studied using the PANSS psychometric scale. In this clinical study, the modern atypical antipsychotic paliperidone was effective in long-term therapy (over 6 months) in patients of Kazakh nationality with schizophrenia across all age groups, with a slight advantage in men over 30 years of age, demonstrating good tolerability and a low risk of undesirable side effects.
Discussion. The clinical observation data obtained in this study on the use of the antipsychotic drug paliperidone in the therapy of paranoid schizophrenia confirm the results of previously conducted foreign and domestic studies regarding the sufficient efficacy and safety of this drug in achieving the most favorable prognosis for this mental disorder. The comparative analysis of data on the efficacy and safety of paliperidone in specific age and gender groups presented in this paper allows for a personalized approach to selecting antipsychotic therapy, taking into account the patient's sex and age, thereby improving their quality of life and social functioning.
Conclusions. Based on the results of the clinical study, it was established that the modern atypical antipsychotic paliperidone is effective in long-term therapy for patients of Kazakh nationality with schizophrenia across all age groups of the adult population, with good tolerability and a low risk of undesirable side effects. The data obtained in this study can serve as the basis for an innovative approach to personalized therapy for patients with paranoid schizophrenia in the Republic of Kazakhstan.
References
1. Bitter I. Negative symptoms of schizophrenia in clinical practice. Oxford University Press, 2020. 120 p.
2. WHO Schizophrenia fact sheet-2025. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia
3. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJ, Vos T. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013 Nov 9;382(9904):1575-86. doi: 10.1016/S0140-6736(13)61611-6. Epub 2013 Aug 29. PMID: 23993280
4. Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou CF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016 Feb 16;12:357-73. doi: 10.2147/NDT.S96649. PMID: 26937191; PMCID: PMC4762470
5. MacEwan JP, Seabury S, Aigbogun MS, Kamat S, van Eijndhoven E, Francois C, Henderson C, Citrome L. Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases. Innov Clin Neurosci. 2016 Aug 1;13(7-8):17-25. PMID: 27672484; PMCID: PMC5022985
6. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012 Mar;25(2):83-8. doi: 10.1097/YCO.0b013e32835035ca. PMID: 22249081
7. Sicras-Mainar A, Maurino J, Ruiz-Beato E, Navarro-Artieda R. Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia. Neuropsychiatr Dis Treat. 2014 Dec 30;11:51-7. doi: 10.2147/NDT.S75449. PMID: 25565850; PMCID: PMC4283985
8. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007 Oct;64(10):1123-31. doi: 10.1001/archpsyc.64.10.1123. PMID: 17909124
9. Magliano L, Marasco C, Fiorillo A, Malangone C, Guarneri M, Maj M; Working Group of the Italian National Study on Families of Persons with Schizophrenia. The impact of professional and social network support on the burden of families of patients with schizophrenia in Italy. Acta Psychiatr Scand. 2002 Oct;106(4):291-8. doi: 10.1034/j.1600-0447.2002.02223.x. PMID: 12225496
10. Mantovani LM, Ferretjans R, Marçal IM, Oliveira AM, Guimarães FC, Salgado JV. Family burden in schizophrenia: the influence of age of onset and negative symptoms. Trends Psychiatry Psychother. 2016 Apr-Jun;38(2):96-9. doi: 10.1590/2237-6089-2015-0082. PMID: 27409135
11. Haller CS, Padmanabhan JL, Lizano P, Torous J, Keshavan M. Recent advances in understanding schizophrenia. F1000Prime Rep. 2014 Jul 8;6:57. doi: 10.12703/P6-57. PMID: 25184047; PMCID: PMC4108956
12. KLOSTERKOTTER J, SCHULTZE-LUTTER F, BECHDOLF A, RUHRMANN S. Prediction and prevention of schizophrenia: what has been achieved and where to go next? World Psychiatry. 2011;10(3):165–174. https://doi.org/10.1002/j.2051-5545.2011.tb00044.x
13. Mathews M. Schizophrenia and Acute Psychosis. August 2013. WHO schizophrenia fact sheet. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia.
14. Sommer IE, Tiihonen J, van Mourik A, Tanskanen A, Taipale H. The clinical course of schizophrenia in women and men-a nation-wide cohort study. NPJ Schizophr. 2020 May 1;6(1):12. doi: 10.1038/s41537-020-0102-z. PMID: 32358572; PMCID: PMC7195359.
15. Li R, Ma X, Wang G, Yang J, Wang C. Why sex differences in schizophrenia? J Transl Neurosci (Beijing). 2016 Sep;1(1):37-42. PMID: 29152382; PMCID: PMC5688947.
16. Brand BA, Haveman YRA, de Beer F, de Boer JN, Dazzan P, Sommer IEC. Antipsychotic medication for women with schizophrenia spectrum disorders. Psychol Med. 2022 Mar;52(4):649-663. doi: 10.1017/S0033291721004591. Epub 2021 Nov 12. Erratum in: Psychol Med. 2023 Jul;53(10):4832. doi: 10.1017/S0033291723001344. PMID: 34763737; PMCID: PMC8961338
17. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:17-54. doi: 10.1016/s0306-4530(02)00125-7. PMID: 12650680
18. Moriarty PJ, Lieber D, Bennett A, White L, Parrella M, Harvey PD, Davis KL. Gender differences in poor outcome patients with lifelong schizophrenia. Schizophr Bull. 2001;27(1):103-13. doi: 10.1093/oxfordjournals.schbul.a006850. PMID: 11215540
19. Riecher-Rössler A, Häfner H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr Scand Suppl. 2000;(407):58-62. doi: 10.1034/j.1600-0447.2000.00011.x. PMID: 11261642
20. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67-76. doi: 10.1093/epirev/mxn001. Epub 2008 May 14. PMID: 18480098
21. Haller CS, Padmanabhan JL, Lizano P, Torous J, Keshavan M. Recent advances in understanding schizophrenia. F1000Prime Rep. 2014 Jul 8;6:57. doi: 10.12703/P6-57. PMID: 25184047; PMCID: PMC4108956
22. Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014 Dec;16(4):505-24. doi: 10.31887/DCNS.2014.16.4/mcarbon. PMID: 25733955; PMCID: PMC4336920
23. Bordet R. Quels critères pour un traitement antipsychotique idéal ? [What criteria for an ideal antipsychotic treatment?]. Encephale. 2015 Feb;41(1):39-46. French. doi: 10.1016/j.encep.2014.12.001. Epub 2015 Jan 28. PMID: 25638050
24. Бурчинский Г.И. Атипичные антипсихотики: проблемы и критерии выбора препарата. Neurоnews. 2017; 4(88):48-52. [Burchinsky GI. Atypical antipsychotics: problems and criteria for drug selection. Neuronews. 2017; 4(88):48-52. (In Russ.)]
25. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007 Feb;90(1-3):147-61. doi: 10.1016/j.schres.2006.09.012. Epub 2006 Nov 7. PMID: 17092691
26. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007 Jul;93(1-3):117-30. doi: 10.1016/j.schres.2007.03.003. Epub 2007 Apr 26. Erratum in: Schizophr Res. 2007 Nov;96(1-3):273-4. PMID: 17466492
27. Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P, Eerdekens M. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007 Feb;27(1):6-14. doi: 10.1097/JCP.0b013e31802dda4a. Erratum in: J Clin Psychopharmacol. 2007 Jun;27(3):258. PMID: 17224706
28. Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry. 2008 May;69(5):817-29. doi: 10.4088/jcp.v69n0515. PMID: 18466043
29. Jones MP, Nicholl D, Trakas K. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. Int J Clin Pharmacol Ther. 2010 Jun;48(6):383-99. doi: 10.5414/cpp48383. PMID: 20497747
30. Barnes TR, Drake R, Paton S, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: an update of the British Association for Psychopharmacology guidelines. Journal of Psychopharmacology. 2020;34(1):3-78. https://journals.sagepub.com/doi/full/10.1177/0269881119889296
31. Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019 Sep 14;394(10202):939-951. doi: 10.1016/S0140-6736(19)31135-3. Epub 2019 Jul 11. Erratum in: Lancet. 2019 Sep 14;394(10202):918. doi: 10.1016/S0140-6736(19)31677-0. PMID: 31303314; PMCID: PMC6891890.
32. Алтынбеков К.С., Незнанов Н.Г. Современные подходы к оптимизации психиатрической помощи больным шизофренией в Республике Казахстан. Алматы: «Издательство», 2017. 188 с. [Altynbekov KS, Neznanov NG. Modern approaches to optimizing psychiatric care for patients with schizophrenia in the Republic of Kazakhstan. Almaty: "Publishing House", 2017. 188 p.].
